Combigene (Sweden) Performance
| COMBI Stock | SEK 2.30 0.02 0.88% |
The firm shows a Beta (market volatility) of 2.83, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Combigene will likely underperform. At this point, Combigene AB has a negative expected return of -0.0536%. Please make sure to confirm Combigene's jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to decide if Combigene AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Combigene AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Combigene is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 48.9 M | |
| Total Cashflows From Investing Activities | -147.7 K | |
| Free Cash Flow | 22 M |
Combigene |
Combigene Relative Risk vs. Return Landscape
If you would invest 250.00 in Combigene AB on November 4, 2024 and sell it today you would lose (20.00) from holding Combigene AB or give up 8.0% of portfolio value over 90 days. Combigene AB is generating negative expected returns and assumes 4.1755% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than Combigene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Combigene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Combigene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Combigene AB, and traders can use it to determine the average amount a Combigene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0128
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | COMBI |
Estimated Market Risk
| 4.18 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Combigene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Combigene by adding Combigene to a well-diversified portfolio.
Combigene Fundamentals Growth
Combigene Stock prices reflect investors' perceptions of the future prospects and financial health of Combigene, and Combigene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Combigene Stock performance.
| Return On Equity | 0.48 | |||
| Return On Asset | 0.21 | |||
| Profit Margin | 0.59 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 125.36 M | |||
| Shares Outstanding | 19.8 M | |||
| Price To Book | 1.06 X | |||
| Price To Sales | 1.62 X | |||
| Revenue | 84.04 M | |||
| EBITDA | 23.56 M | |||
| Cash And Equivalents | 34.09 M | |||
| Cash Per Share | 1.72 X | |||
| Book Value Per Share | 8.29 X | |||
| Cash Flow From Operations | 22.11 M | |||
| Earnings Per Share | 3.68 X | |||
| Total Asset | 166.22 M | |||
| Retained Earnings | (5 M) | |||
| Current Asset | 11 M | |||
About Combigene Performance
Assessing Combigene's fundamental ratios provides investors with valuable insights into Combigene's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Combigene is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
CombiGene AB engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. CombiGene AB was founded in 1999 and is headquartered in Lund, Sweden. Combigene operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 7 people.Things to note about Combigene AB performance evaluation
Checking the ongoing alerts about Combigene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Combigene AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Combigene AB generated a negative expected return over the last 90 days | |
| Combigene AB has high historical volatility and very poor performance | |
| About 31.0% of the company shares are held by company insiders |
- Analyzing Combigene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Combigene's stock is overvalued or undervalued compared to its peers.
- Examining Combigene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Combigene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Combigene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Combigene's stock. These opinions can provide insight into Combigene's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Combigene Stock Analysis
When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.